Clinical Trial Update: BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity [Phase 3]

View source ↗

Summary

Phase 3 trial comparing BI 695501 to Humira in active Crohn's disease completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• BI 695501
• Humira (adalimumab)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Crohn Disease | Phase 3 | Status: COMPLETED | Results posted: 2020-06-04